- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Phase 3 Migraine Trial of DHE in Nasal Form Fails to Show Significant Difference
A formulation of dihydroergotamine (DHE) in a nasal powder form was no different than placebo for relief from pain and annoying symptoms at 2 hours post dose.
An effort to create a treatment for acute migraine pain out of a reformulated existing drug suffered a setback Thursday, as biopharmaceutical firm Satsuma Pharmaceuticals said a late-stage trial of its dihydroergotamine (DHE) nasal powder did not reach statistical significance.
In a statement, the company said the drug, STS101, was no different from placebo at either of the 2 co-primary end points: freedom from pain and relief of the most bothersome symptom (including photophobia, phonophobia, or nausea) at 2 hours post administration. The phase 3 trial, EMERGE, tested STS101 at 2 dosages: 3.9 mg and 5.2 mg.
The company said the drug was well tolerated, with no reports of serious adverse events and low adverse event rates. Topline data showed numerical differences vs placebo for both dosages, and the company said both dosages were significantly better than placebo at 3 hours post administration and at later times.
The president and CEO of Satsuma, John Kollins, said the firm was “surprised and disappointed” at the results and that the company would be continuing the analysis of trial data and considering its future business plans. Satsuma said it had cash, cash equivalents, and marketable securities of $93.7 million as of June 30, 2020.
The phase 3 EMERGE efficacy trial is a multicenter, single-dose, randomized, double-blind, placebo-controlled, parallel group US study with more than 1140 patients.
Participants were randomized (1:1:1) to receive 1 of 3 treatments: DHE 3.9 mg, DHE 5.2 mg, or matching placebo to use during their next migraine attack of at least moderate pain severity. The trial was statistically designed for greater than 99% power for the freedom-from-pain end point and greater than 95% power for the freedom-from-most-bothersome-symptom endpoint.
DHE is a derivative of ergotamine. A recent article called it “an older drug with an interesting history.” It is currently indicated for migraine in the United States via intravenous, intramuscular, and subcutaneous routes; it is also used in other countries in additional formulations. It was also the treatment for acute migraines before the development of triptans.
How Can Digital Care Programs Aid Those With Chronic Musculoskeletal Pain?
June 9th 2020On this episode of Managed Care Cast, we speak with Jeffrey Krauss, MD, chief medical officer of Hinge Health and Stanford Clinical assistant professor, about the efficacy of a 12-week digital care program aimed to reduce lower back and knee pain in a real-world population.
Listen
Understanding the Impact of Inappropriate Opioid Prescribing Practices
April 19th 2019Deaths from drug overdoses have become the leading cause of death for Americans under age 50, which can largely be attributed to prescription opioids. Due to the role of prescription opioids, understanding prescribing patterns and identifying inappropriate prescribing are crucial for changing the course of the epidemic.
Listen
MBSR Reduced Pain Perception in Patients With Migraine
December 19th 2020The finding about mindfulness-based stress reduction (MBSR) was a secondary outcome of the double-blinded, randomized, placebo-controlled clinical trial. The primary outcome—a reduction in the frequency of migraines—was not reached.
Read More
